DHB & Sodium Valproate
Dihydroboldenone (DHB) is a synthetic anabolic-androgenic steroid structurally related to boldenone, discussed primarily in bodybuilding contexts for its strong androgenic and anabolic effects. It is not approved for medical use in most countries and is associated with risks typical of anabolic steroids, including hormonal suppression and cardiovascular concerns.
Sodium valproate is a prescription medication used clinically to treat epilepsy, bipolar disorder, and migraine prevention. It works by stabilizing neural activity through effects on GABA signaling and other cellular pathways. Outside of approved indications, any experimentation carries significant risks and requires medical supervision due to potential liver, metabolic, and neurological side effects.
-
This page summarizes anecdotal reports and community observations, not medical evidence. Reports may be incomplete, biased or inaccurate and are not medical advice or recommendations. “Risk” here refers to how frequently severe or prolonged symptom worsening is reported, not to proven causation or population-wide probability. Individual responses vary widely, and absence of issues in some users does not rule out significant reactions in others.
-
Within PFS/PSSD/PAS communities, the DHB + sodium valproate combination is discussed in relation to its potential interactions with androgen receptor signaling, epigenetic regulation, and GABAergic pathways. The theoretical rationale described by users combines three proposed targets: (1) strong androgen receptor activation (DHB), (2) epigenetic modulation via HDAC inhibition (valproate), and (3) GABAergic system effects (valproate), which some hypothesize could intersect with pathways implicated in persistent post-drug syndromes. Some write-ups frame this as an attempt to "force a reset" of dysregulated androgen signaling and downstream gene expression. It's important to emphasize that this rationale is theoretical, extrapolated from known pharmacology rather than validated in controlled studies for PFS/PSSD/PAS. These mechanisms may interact with pathways involving androgen receptor signaling, HDAC inhibition/epigenetic regulation, or GABAergic modulation that are often discussed in relation to PFS / PSSD / PAS.
-
Sustained Improvement Anecdotes. Highly Experimental w/ High Risks & Complexity:
Within PFS/PSSD/PAS communities, the DHB + sodium valproate protocol appears in a small number of highly visible anecdotes describing major improvement or even “full recovery.” These reports tend to stand out because of their dramatic nature. At the same time, many individuals report no meaningful benefit, and others describe partial, temporary, or unstable improvements that do not persist. Importantly, there are also reports of significant harm, including severe hormonal suppression, neuropsychiatric destabilization, prolonged crashes, and difficulty returning to baseline after stopping. Because these accounts involve extreme interventions, complex timing, underground sourcing, and multiple uncontrolled variables, they should be interpreted as signals of experimentation rather than evidence of efficacy.
Across reports, outcomes appear highly polarized—ranging from dramatic improvement to serious worsening—with relatively few neutral or predictable responses. This clustering at the extremes has led many community members to describe the protocol as high-risk and high-uncertainty, rather than a reproducible or broadly applicable approach.
Given the pharmacology involved, this volatility is not surprising. DHB can profoundly suppress endogenous hormone production and carries known anabolic-steroid risks (endocrine suppression, cardiovascular strain, lipid changes, fertility effects). Sodium valproate has a well-established risk profile, including liver toxicity, metabolic effects, cognitive dulling, teratogenicity, and clinically significant drug interactions. Combining the two introduces additional uncertainty, and abrupt changes (initiation, cessation, contamination, or dosing errors) are frequently cited in worsening anecdotes. Community anecdotes involving worsening also mention difficulties sourcing pure DHB, with several anecdotes reporting crashing due to the DHB not being pure and being cut with Testosterone, resulting in T and E spiking during the protocol and potential interrupting DHB’s binding to the AR.
For these reasons, many in the community explicitly frame this protocol as a last-resort or do-not-attempt category, rather than something to trial casually or without close medical supervision.
Evidence Basis: Established pharmacology and safety literature on anabolic–androgenic steroids and sodium valproate; mechanistic discussions involving androgen receptor signaling, HDAC inhibition, and GABA modulation; anecdotal community reports (online forums, self-reports). No controlled studies demonstrate safety or efficacy of this protocol for PFS/PSSD/PAS.
-
Public comments reflect individual experiences and opinions. They are not medical advice and may not be accurate or representative.